A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis

Lorinda Chung; David Fiorentino

doi:10.1016/j.jaad.2006.02.004

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis

J Am Acad Dermatol. 2006 May;54(5):880-2. doi: 10.1016/j.jaad.2006.02.004.

Authors

Lorinda Chung¹, David Fiorentino

Affiliation

¹ Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California 94305, USA.

PMID: 16635673
DOI: 10.1016/j.jaad.2006.02.004

Abstract

We performed a pilot trial of subcutaneous treprostinil for the treatment of digital ulcers in scleroderma. Of the 5 patients completing therapy, ulcer size significantly decreased and no new ulcers occurred on continuous therapy. Although effective, the high rate of injection site reactions may limit the utility of this therapy.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Epoprostenol / administration & dosage
Epoprostenol / analogs & derivatives*
Epoprostenol / therapeutic use
Female
Fingers / pathology
Humans
Injections, Subcutaneous
Male
Middle Aged
Scleroderma, Systemic / complications*
Skin Ulcer / etiology
Skin Ulcer / prevention & control*
Treatment Outcome

Substances

Epoprostenol
treprostinil